The modulatory mechanisms of fenofibrate on human primary T cells

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 4, 2010, Pages 316-324

  Cheng, Shu Meng ^a   Chu, Kai Min ^a   Lai, Jenn Haung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Activator protein 1; Cytokine; Fenofibrate; T cells

Indexed keywords

CYTOKINE; FENOFIBRATE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ANTILIPEMIC AGENT; AUTACOID; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; IMMUNOLOGY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; OSMOLARITY; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; BLOTTING, WESTERN; CYTOKINES; DNA-BINDING PROTEINS; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; LYMPHOCYTE ACTIVATION; NF-KAPPA B; OSMOLAR CONCENTRATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROCETOFEN; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; FENOFIBRATE; HYPOLIPIDEMIC AGENTS;

EID: 77953540416     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.04.003     Document Type: Article

References (66)

1. Adhikari N., Charles N., Lehmann U., Hall J.L. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr. Atheroscler. Rep. 2006, 8:252-260.
2. Balfour J.A., McTavish D., Heel R.C. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990, 40:260-290.
3. Barter P.J., Rye K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler. Thromb. Vasc. Biol. 2008, 28:39-46.
4. Bea F., Kreuzer J., Preusch M., Schaab S., Isermann B., Rosenfeld M.E., Katus H., Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2787-2792.
5. Belalcazar L.M., Ballantyne C.M. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog. Cardiovasc. Dis. 1998, 41:151-174.
6. BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
7. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2137-2142.
8. Buttice G., Miller J., Wang L., Smith B.D. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ. Res. 2006, 98:472-479.
9. Chapman M.J. Pharmacology of fenofibrate. Am. J. Med. 1987, 83:21-25.
10. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
11. Chen D.M., Cai X., Kwik-Uribe C.L., Zeng R., Zhu X.Z. Inhibitory effects of procyanidin B(2) dimer on lipid-laden macrophage formation. J. Cardiovasc. Pharmacol. 2006, 48:54-70.
12. Cheng S.M., Yang S.P., Ho L.J., Tsao T.P., Lai J.H. Down-regulation of c-jun N-terminal kinase-activator protein-1 signaling pathway by ginkgo biloba extract in human peripheral blood T cells. Biochem. Pharmacol. 2003, 66:679-689.
13. Clark R., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., Padula S. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 2000, 164:1364-1371.
14. Committee of Principal Investigators A cooperative trial in the prevention of ischemic heart disease using clofibrate. Br. Heart J. 1978, 40:1069-1118.
15. Cunard R., Ricoto M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 2002, 168:2795-2802.
16. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 2003, 163:1117-1125.
17. de Faire U., Ericsson C.G., Grip L., Nilsson J., Svane B., Hamsten A. Retardation of coronary atherosclerosis: the bezafibrate coronary atherosclerosis intervention trial (BECAIT) and other angiographic trials. Cardiovasc. Drugs Ther. 1997, 11(Suppl. 1):257-263.
18. De Silva D.S., Wilson R.M., Hutchinson C., Ip P.C., Garcia A.G., Lancel S., Ito M., Pimentel D.R., Sam F. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am. J. Physiol.-Heart C 2009, 296:H1983-H1993.
19. Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 2003, 198:411-421.
20. Drouin P., Mejean L., Lambert D. Drug plasma levels and hypocholesterolemic effect of fenofibrate in patients with type IIa hyperlipoproteinemia. Curr. Ther. Res. 1979, 26:357-362.
21. Foletta V.C., Segal D.H., Cohen D.R. Transcriptional regulation in the immune system: all roads lead to AP-1. J. Leukoc. Biol. 1998, 63:139-152.
22. Ford E.S., Zhao G., Pearson W.S., Mokdad A.H. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch. Intern. Med. 2009, 169:572-578.
23. Frick M.H., Syvänne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesäniemi Y.A., Pasternack A., Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137-2143.
24. Frostegard J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U., Hansson G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
25. Ginsberg H.N. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am. J. Cardiol. 2001, 87:1174-1180.
26. Glass C.K., Witztum J.L. Atherosclerosis: the road ahead. Cell 2001, 104:503-516.
27. Hansson G.K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 1989, 135:169-175.
28. Harvengt C., Heller F., Desager J.P. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 1980, 7:73-82.
29. Ho L.J., Wang J.J., Shaio M.F., Kao C.L., Chang D.M., Han S.W., Lai J.H. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 2001, 166:1499-1506.
30. Hogue J.C., Lamarche B., Deshaies Y., Tremblay A.J., Bergeron J., Gange C., Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 2008, 57:246-254.
31. Hosono M., de Boer O.J., van der Wal A.C., van der Loos C.M., Teeling P., Piek J.J., Ueda M., Becker A.E. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 2003, 168:73-80.
32. Jacobson T.A., Miller M., Schaefer E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 2007, 29:763-777.
33. Jeanpierre E., Le Tourneau T., Zawadzki C., Van Belle E., Mouquet F., Susen S., Ezekowitz M.D., Staels B., Jude B., Corseaux D. Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. Cardiovasc. Pathol. 2009, 18:140-147.
34. Jeong S., Yoon M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. Exp. Mol. Med. 2009, 41:397-405.
35. Johnson D.R., Hauser I.A., Voll R.E., Emmrich F. Arterial and venular endothelial cell costimulation of cytokine secretion by human T cell clones. J. Leukoc. Biol. 1998, 63:612-619.
36. Jonasson L., Holm J., Skalli O., Gabbiani G., Hansson G.K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 1985, 76:125-131.
37. Jukema J.W., Bruschke A.V., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., van Rappard F.M., Lie K.I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
38. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 1997, 9:240-246.
39. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22:456-461.
40. Kostadinova R., Wahli W., Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem. 2005, 12:2995-3009.
41. Lai J.H., Ho L.J., Kwan C.Y., Chang D.M., Lee T.C. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation 1999, 68:1383-1392.
42. Lai J.H., Ho L.J., Lu K.C., Chang D.M., Shaio M.F., Han S.H. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J. Immunol. 2001, 166:6914-6924.
43. Lai J.H., Horvath G., Subleski J., Bruder J., Ghosh P., Tan T.H. Rel A is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell. Biol. 1995, 15:4260-4271.
44. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariety J., Nicoleti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
45. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
46. Lo Y.Y.C., Cruz T.F. Involvement of reactive oxygen species in cytokine and growth induction of c-fos expression in chondrocytes. J. Biol. Chem. 1995, 270:11727-11730.
47. Loppnow H., Werdan K., Buerke M. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun. 2008, 14:63-87.
48. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J., Diab A., Drew P.D., Racke M.K. PPARα agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
49. Madej A., Okopien B., Kowalski J., Zielinski M., Wyscocki J., Szygula B., Kalina Z., Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 1998, 36:345-349.
50. Mansouri R.M., Bauge E., Gervois P., Fruchart-Najib J., Fievet C., Staeks B., Fruchart J.C. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ. Res. 2008, 103:450-453.
51. Marx N., Kehrle B., Kohlhammer K., Grüb M., Koenig W., Hombach V., Libby P., Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes. Circ. Res. 2002, 90:703-710.
52. Nencioni A., Grunebach F., Zobywlaski A., Denzlinger C., Brugger W., Brossart P. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J. Immunol. 2002, 169:1228-1235.
53. Okopien B., Krysiak R., Kowalski J., Madej A., Belowski D., Zielinski M., Labuzek K., Herman Z.S. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004, 176:327-335.
54. Paoletti R., Gotto A.M., Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109:III20-III26.
55. Qi C., Zhu Y., Reddy J. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell. Biochem. Biophys. 2000, 32:187-204.
56. Racke M.K., Gocke A.R., Muir M., Diab A., Paul D., Drew P.D., Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 2006, 136:700-703.
57. Rosenson R.S. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am. Heart J. 2008, 155. 499.e9-16.
58. Rosenson R.S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity 2009, 17:504-509.
59. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
60. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low-density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:3893-3897.
61. Thompson G.R., Hollyer J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr. Opin. Lipidol. 1995, 6:386-388.
62. Tsimihodimos V., Liberopoulos E., Elisaf M. Pleiotropic effects of fenofibrate. Curr. Pharm. Des. 2009, 15:517-528.
63. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
64. Walch L., Massade L., Dufilho M., Brunet A., Rendu F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 2006, 187:285-291.
65. Woerly G., Honda K., Loyens M., Papin J., Auwerx J., Staels B., Capron M., Racke M.K., Gocke A.R., Muir M., Diab A., Drew P.D., Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 2003, 136:700-703.
66. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919-2922.